177 related articles for article (PubMed ID: 33385372)
1. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer.
Pindiprolu SKSS; Krishnamurthy PT; Dev C; Chintamaneni PK
Chem Phys Lipids; 2021 Mar; 235():105033. PubMed ID: 33385372
[TBL] [Abstract][Full Text] [Related]
2. Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells.
Pindiprolu SKSS; Chintamaneni PK; Krishnamurthy PT; Ratna Sree Ganapathineedi K
Drug Dev Ind Pharm; 2019 Feb; 45(2):304-313. PubMed ID: 30348020
[TBL] [Abstract][Full Text] [Related]
3. Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro.
Eskiler GG; Cecener G; Dikmen G; Egeli U; Tunca B
Curr Drug Deliv; 2019; 16(6):511-529. PubMed ID: 31113350
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and
Darabi F; Saidijam M; Nouri F; Mahjub R; Soleimani M
Biomed Res Int; 2022; 2022():6253978. PubMed ID: 35845934
[TBL] [Abstract][Full Text] [Related]
6. Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line.
Bhatt H; Rompicharla SVK; Komanduri N; Aashma S; Paradkar S; Ghosh B; Biswas S
Curr Drug Deliv; 2018; 15(9):1271-1283. PubMed ID: 29732970
[TBL] [Abstract][Full Text] [Related]
7. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
[TBL] [Abstract][Full Text] [Related]
8. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
9. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.
Azzam DJ; Zhao D; Sun J; Minn AJ; Ranganathan P; Drews-Elger K; Han X; Picon-Ruiz M; Gilbert CA; Wander SA; Capobianco AJ; El-Ashry D; Slingerland JM
EMBO Mol Med; 2013 Oct; 5(10):1502-22. PubMed ID: 23982961
[TBL] [Abstract][Full Text] [Related]
10. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
11. Clathrin-mediated endocytic uptake of PUFA enriched self-nanoemulsifying lipidic systems (SNELS) of an anticancer drug against triple negative cancer and DMBA induced preclinical tumor model.
Khurana RK; Kumar R; Gaspar BL; Welsby G; Welsby P; Kesharwani P; Katare OP; Singh KK; Singh B
Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():645-658. PubMed ID: 30033299
[TBL] [Abstract][Full Text] [Related]
12. Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.
Fancy RM; Kim H; Napier T; Buchsbaum DJ; Zinn KR; Song Y
J Cell Biochem; 2018 Jul; 119(7):6216-6230. PubMed ID: 29663486
[TBL] [Abstract][Full Text] [Related]
13. Phenyl boronic acid-modified lipid nanocarriers of niclosamide for targeting triple-negative breast cancer.
Ss Pindiprolu SK; Krishnamurthy PT; Ghanta VR; Chintamaneni PK
Nanomedicine (Lond); 2020 Jul; 15(16):1551-1565. PubMed ID: 32618501
[No Abstract] [Full Text] [Related]
14. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
15. Gamma-secretase inhibitor, a potential target therapy for MUC2-positive colorectal carcinoma.
Bu X; Li N; Tian X; Huang P
Neoplasma; 2011; 58(4):343-7. PubMed ID: 21520992
[TBL] [Abstract][Full Text] [Related]
16. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780.
Wang M; Wu L; Wang L; Xin X
Biochem Biophys Res Commun; 2010 Feb; 393(1):144-9. PubMed ID: 20117093
[TBL] [Abstract][Full Text] [Related]
18. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
Godugu C; Doddapaneni R; Singh M
Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol loaded oxidized mesoporous carbon nanoparticles: A promising tool to treat triple negative breast cancer.
Fan C; Kong F; Shetti D; Zhang B; Yang Y; Wei K
Biochem Biophys Res Commun; 2019 Nov; 519(2):378-384. PubMed ID: 31519327
[TBL] [Abstract][Full Text] [Related]
20. Phenylboronic acid modified lipid nanocarriers mediated co-delivery of immunocytokine TRAIL and gamma-secretase inhibitor to triple negative breast cancer cells and cancer stem cells.
Pindiprolu SKSS; Avasarala H; Dinakaran SK
Med Hypotheses; 2021 Dec; 157():110716. PubMed ID: 34731681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
